• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Axogen, Inc. to Participate in the J.P. Morgan 2026 Healthcare Conference

    12/17/25 7:00:00 AM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $AXGN alert in real time by email

    ALACHUA, Fla. and TAMPA, Fla., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that the company will be participating in the upcoming J.P. Morgan 2026 Healthcare Conference.

    Axogen's management is scheduled to present on Thursday, January 15, 2026, at 10:30 AM Pacific Standard Time. Interested parties may access a live audio webcast of the presentation by visiting the "Investors" section of the company's website at ir.axogeninc.com.

    About Axogen

    Axogen (NASDAQ:AXGN) is focused on the science, development and commercialization of technologies for peripheral nerve repair. With a mission to make nerve repair the expected standard of care, Axogen advances the field through research, education, and collaboration with surgeons and healthcare providers across a global network.

    Axogen's product portfolio includes Avance® (acellular nerve allograft-arwx), Axoguard Nerve Connector®, Axoguard Nerve Protector®, Axoguard HA+ Nerve Protector™, Axoguard Nerve Cap®, and Avive+ Soft Tissue Matrix™. The Axogen portfolio of products is available in the United States, Canada, Germany, the United Kingdom, Spain and several other countries.​

    For more information, visit www.axogeninc.com.





    Contact:
    Axogen, Inc.
    [email protected]

    Primary Logo

    Get the next $AXGN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AXGN

    DatePrice TargetRatingAnalyst
    12/1/2025$40.00Outperform
    Mizuho
    3/17/2025$30.00Buy
    Lake Street
    7/1/2024$13.00Outperform
    Raymond James
    11/11/2022$15.00Buy
    Jefferies
    5/9/2022$10.00 → $15.00Hold → Buy
    Canaccord Genuity
    3/11/2022$21.00Overweight
    Cantor Fitzgerald
    11/4/2021$25.00 → $20.00Market Outperform
    JMP Securities
    More analyst ratings

    $AXGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Wendell Amy Mcbride sold $1,280,465 worth of shares (43,684 units at $29.31) and exercised 43,684 shares at a strike of $6.91 (SEC Form 4)

    4 - Axogen, Inc. (0000805928) (Issuer)

    12/17/25 4:25:23 PM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Weiler Kathy Johnson exercised 40,073 shares at a strike of $6.99 and sold $1,378,476 worth of shares (46,653 units at $29.55), closing all direct ownership in the company (SEC Form 4)

    4 - Axogen, Inc. (0000805928) (Issuer)

    12/17/25 4:25:04 PM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CFO Hartley Lindsey Marie exercised 14,812 shares at a strike of $8.27 and sold $442,294 worth of shares (14,812 units at $29.86) (SEC Form 4)

    4 - Axogen, Inc. (0000805928) (Issuer)

    12/17/25 4:24:49 PM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AXGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Mizuho initiated coverage on AxoGen with a new price target

    Mizuho initiated coverage of AxoGen with a rating of Outperform and set a new price target of $40.00

    12/1/25 8:24:55 AM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Lake Street initiated coverage on AxoGen with a new price target

    Lake Street initiated coverage of AxoGen with a rating of Buy and set a new price target of $30.00

    3/17/25 8:23:19 AM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Raymond James initiated coverage on AxoGen with a new price target

    Raymond James initiated coverage of AxoGen with a rating of Outperform and set a new price target of $13.00

    7/1/24 7:31:31 AM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AXGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $AXGN
    SEC Filings

    View All

    Axogen, Inc. to Participate in the J.P. Morgan 2026 Healthcare Conference

    ALACHUA, Fla. and TAMPA, Fla., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that the company will be participating in the upcoming J.P. Morgan 2026 Healthcare Conference. Axogen's management is scheduled to present on Thursday, January 15, 2026, at 10:30 AM Pacific Standard Time. Interested parties may access a live audio webcast of the presentation by visiting the "Investors" section of the company's website at ir.axogeninc.com. About Axogen Axogen (NASDAQ:AXGN) is focused on the science, development and commercialization of techno

    12/17/25 7:00:00 AM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Axogen Announces FDA Approval of Biologics License Application for AVANCE® (acellular nerve allograft–arwx)

    ALACHUA, Fla. and TAMPA, Fla., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical technologies for the restoration of peripheral nerve function, today announced that the U.S. Food and Drug Administration (the "FDA") has approved the Biologics License Application ("BLA") for AVANCE® (acellular nerve allograft-arwx). Avance is an acellular nerve scaffold for the treatment of adult and pediatric patients aged 1 month or older with sensory, mixed, and motor peripheral nerve discontinuities. The indications for sensory nerve discontinuities >25mm and for mixed and motor nerve discontinuities were approved under FDA's A

    12/3/25 8:01:25 PM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences

    ALACHUA, Fla. and TAMPA, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that management is scheduled to participate in three upcoming investor conferences: Jefferies Global Healthcare Conference (London)Participation: Fireside chat and 1x1 investor meetingsDate/Time: Fireside Chat Tuesday, November 18, 2025, 4:30 PM GMTWebcast Link: Jefferies/Axogen Fireside Chat Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum (NYC)Participation: 1x1 investor meetings onlyDate/Time: Thursday, November 20, 2025 Piper Sa

    11/4/25 7:00:00 AM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 144 filed by Axogen Inc.

    144 - Axogen, Inc. (0000805928) (Subject)

    12/16/25 4:27:18 PM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 144 filed by Axogen Inc.

    144 - Axogen, Inc. (0000805928) (Subject)

    12/9/25 4:40:15 PM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 144 filed by Axogen Inc.

    144 - Axogen, Inc. (0000805928) (Subject)

    12/9/25 4:39:44 PM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AXGN
    Leadership Updates

    Live Leadership Updates

    View All

    Axogen Announces Chief Financial Officer Transition

    ALACHUA, Fla. and TAMPA, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the appointment of Lindsey Hartley, CPA, as Chief Financial Officer, effective May 12, 2025. Ms. Hartley, who currently serves as Vice President, Corporate Controller at Axogen, will succeed Nir Naor, who is departing to pursue other opportunities. Mr. Naor will remain with the Company in an advisory capacity until July 1, 2025, to ensure a smooth transition. "I want to express my sincere gratitude to Nir for his service to Axogen," said Michael Dale, President, Chief Executive O

    5/8/25 7:00:00 AM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Axogen Announces Appointment of Rick Ditto as Vice President, Global Health Economics, Reimbursement & Policy, and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    ALACHUA, Fla. and TAMPA, Fla., March 24, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the appointment of Rick Ditto as Vice President, Global Health Economics, Reimbursement & Policy. Mr. Ditto will report to Michael Dale, President, and Chief Executive Officer, and will lead the development of the coverage and reimbursement-related strategies required to support Axogen's mission to establish restoration of peripheral nerve function as an expected standard of care. Mr. Ditto brings over 15 years of leadership experience in the medical device industry, with a pr

    3/24/25 8:00:00 AM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Axogen Announces Appointment of Jesse Bishop as Vice President of Regulatory Affairs and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    ALACHUA, Fla. and TAMPA, Fla., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the appointment of Jesse Bishop as Vice President of Regulatory Affairs. Mr. Bishop will report to Michael Dale, President, and Chief Executive Officer, and will lead the development and execution of domestic and international regulatory strategies to advance company objectives related to new product development, market approval, market development and other regulatory initiatives. Mr. Bishop will oversee all facets of Axogen's regulatory affairs, maintenance of Axogen product

    2/3/25 8:00:00 AM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AXGN
    Financials

    Live finance-specific insights

    View All

    Axogen, Inc. Reports Third Quarter 2025 Financial Results

    ALACHUA, Fla. and TAMPA, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today reported financial results and business highlights for the third quarter ended September 30, 2025. Third Quarter Financial Results Third quarter revenue was $60.1 million, a 23.5% increase compared to the third quarter of 2024, and a 6.0% increase over the second quarter of 2025.For the third quarter of 2025, gross margin was 76.6%, up from 74.9% for the third quarter of 2024, and up from 74.2% in the second quarter of 2025.Net income for the quarter was $0.7 million,

    10/29/25 7:00:00 AM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Axogen, Inc. to Report 2025 Third Quarter Financial Results on October 29, 2025

    ALACHUA, Fla. and TAMPA, Fla., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it will report 2025 third quarter financial results on Wednesday, October 29, 2025, before the market opens. Axogen management will host an investment-community conference call and webcast at 8 a.m. ET following the release. Investors interested in participating in the conference call by phone may do so by dialing toll free at (877) 407-0993 or use the direct dial-in number at (201) 689-8795. A live webcast, archived replay, and presentation slides of t

    10/15/25 7:00:00 AM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Axogen, Inc. Reports Second Quarter 2025 Financial Results

    ALACHUA, Fla. and TAMPA, Fla., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today reported financial results and business highlights for the second quarter ended June 30, 2025. Second Quarter Financial Results Second quarter revenue was $56.7 million, an 18.3% increase compared to the second quarter of 2024, and a 16.7% increase over the first quarter of 2025.For the second quarter of 2025, gross margin was 74.2%, up from 73.8% for the second quarter of 2024, and up from 71.9% in the first quarter of 2025.Net income for the quarter was $0.6

    8/5/25 7:00:00 AM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AXGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Axogen Inc.

    SC 13G/A - Axogen, Inc. (0000805928) (Subject)

    11/14/24 3:31:14 PM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by Axogen Inc.

    SC 13G - Axogen, Inc. (0000805928) (Subject)

    11/7/24 4:34:48 PM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13G/A filed by Axogen Inc.

    SC 13G/A - Axogen, Inc. (0000805928) (Subject)

    9/10/24 4:00:03 PM ET
    $AXGN
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care